Key Points
- Oruka Therapeutics insider Joana Goncalves sold 7,000 shares for $706,720 at an average price of $100.96, reducing her position by 18.05% to 31,771 shares. The sale was made under a pre-arranged Rule 10b5-1 plan.
- Oruka reported quarterly EPS of -$0.63, missing analyst expectations of -$0.60; analysts forecast a full-year loss of $2.52 per share.
- Analyst sentiment is mostly positive: nine analysts rate ORKA Buy and one rates it Sell, for a consensus “Moderate Buy” rating and $141.80 price target.
Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) insider Joana Goncalves sold 7,000 shares of the stock in a transaction that occurred on Monday, November 16th. The shares were sold at an average price of $100.96, for a total value of $706,720.00. Following the completion of the sale, the insider directly owned 31,771 shares of the company's stock, valued at approximately $3,207,600.16. The trade was a 18.05% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Joana Goncalves also recently made the following trade(s):
- On Thursday, October 15th, Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock. The shares were sold at an average price of $74.81, for a total transaction of $523,670.00.
- On Tuesday, September 15th, Joana Goncalves sold 7,947 shares of Oruka Therapeutics stock. The shares were sold at an average price of $92.38, for a total transaction of $734,143.86.
Oruka Therapeutics Stock Performance
Shares of ORKA opened at $99.24 on Tuesday. Oruka Therapeutics, Inc. has a 1-year low of $25.23 and a 1-year high of $115.51. The company's fifty day simple moving average is $89.81 and its 200 day simple moving average is $72.68.
Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last posted its quarterly earnings results on Monday, November 9th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.03). Equities analysts forecast that Oruka Therapeutics, Inc. will post -2.52 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in ORKA. Nykredit A S bought a new stake in Oruka Therapeutics in the 2nd quarter valued at $29,000. GAMMA Investing LLC lifted its holdings in Oruka Therapeutics by 201.6% during the 3rd quarter. GAMMA Investing LLC now owns 374 shares of the company's stock valued at $31,000 after purchasing an additional 250 shares during the last quarter. Orion Capital Management LLC acquired a new stake in Oruka Therapeutics during the 2nd quarter valued at $91,000. Sterling Capital Management LLC boosted its position in Oruka Therapeutics by 839.0% during the third quarter. Sterling Capital Management LLC now owns 1,662 shares of the company's stock worth $138,000 after purchasing an additional 1,485 shares during the period. Finally, Natural Investments LLC bought a new position in Oruka Therapeutics during the second quarter worth $202,000. 56.44% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
Several research firms have recently weighed in on ORKA. Weiss Ratings restated a "sell (d-)" rating on shares of Oruka Therapeutics in a research note on Tuesday, October 13th. BTIG Research reaffirmed a "buy" rating and issued a $151.00 target price on shares of Oruka Therapeutics in a report on Tuesday, November 10th. Wall Street Zen downgraded shares of Oruka Therapeutics from a "hold" rating to a "sell" rating in a research note on Sunday, August 16th. HC Wainwright reiterated a "buy" rating on shares of Oruka Therapeutics in a report on Tuesday, October 27th. Finally, Mizuho set a $120.00 price target on Oruka Therapeutics in a report on Thursday, September 3rd. Nine investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Oruka Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $141.80.
Get Our Latest Stock Report on ORKA
About Oruka Therapeutics
(
Get Free Report)
Oruka Therapeutics is a clinical-stage biotechnology company developing long-acting antibody medicines for chronic inflammatory skin diseases. Its research focuses on pathways involved in conditions such as plaque psoriasis, with the goal of extending the time between treatments. The company's pipeline includes ORKA-001, an antibody targeting interleukin-23 (IL-23), and ORKA-002, which targets interleukin-17A and interleukin-17F (IL-17A/F). Both programs are being developed as potential treatments for inflammatory skin conditions.
Further Reading

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].